Loading…
Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing
Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing processes and treatment strategies are major limitations. Our...
Saved in:
Published in: | BMC immunology 2023-06, Vol.24 (1), p.14-14, Article 14 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c549t-6e41f22cf780a2cc175010a9324b888aebaf351ff6fb21a17f8c4c9a5256e8623 |
container_end_page | 14 |
container_issue | 1 |
container_start_page | 14 |
container_title | BMC immunology |
container_volume | 24 |
creator | Lee, Yi-Yen Luo, Shao-Ciao Lee, Chung-Hsin Tang, Chien-Lun Shen, Chiung-Chyi Cheng, Wen-Yu Yang, Yi-Chin Yang, Meng-Yin Yen, Chun-Ming |
description | Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing processes and treatment strategies are major limitations. Our study used tumor lysate as a tumor-associated antigen source and DCs and CIK cells in coculture. We developed an efficient method to obtain autologous DCs- and CIK cells from peripheral blood. We used flow cytometry to assess DC activation and the cytometric bead array assay to quantify cytokines secreted by CIK cells.
We evaluated the antitumor activity of DC- CIK coculture in vitro with the K562 cell line. We demonstrated that a manufacturing process employing frozen immature DCs can yield the lowest loss with the highest economic benefits. DC-CIK coculture can effectively upgrade CIK cells' immunological specificity to tumors in the presence of tumor-associated antigens.
In vitro experiments revealed that when the DC- CIK cell ratio was 1: 20 in the coculture, CIK cells secreted the highest number of cytokines on the 14th day and the antitumor immune effect showed the highest potency. CIK cells' cytotoxicity to K562 cells was highest when the CIK: K562 cell ratio was 25: 1. We developed an efficient manufacturing process for DC- CIK coculture, while also establishing the optimal DC- CIK cell ratio for immunological activity and the best cytotoxic CIK: K562 cell ratio. |
doi_str_mv | 10.1186/s12865-023-00552-5 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1fe56ad9587c4d0f886c3b53f53cf081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A755318568</galeid><doaj_id>oai_doaj_org_article_1fe56ad9587c4d0f886c3b53f53cf081</doaj_id><sourcerecordid>A755318568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-6e41f22cf780a2cc175010a9324b888aebaf351ff6fb21a17f8c4c9a5256e8623</originalsourceid><addsrcrecordid>eNptkstu1DAYhSMEoqXwAixQJDawSPEljj0rVFVcRqpUicva8ji_M24Te_Cl6vBevB-eSSkdhLJw9Ps7J_HxqaqXGJ1iLLp3ERPRsQYR2iDEGGnYo-oYtxw3BHPy-MH7UfUsxiuEMBdEPK2OKKeia9v2uPp1uUl2sj-tG-qUJx8aFaPXViXoa-WSHcA1sSB5nEc5-dEPPse6B9cHm6yuNYxjgftab5O_tg4a6_qsC35txxHCDGiv85hygDr5GtxaOQ17RfK3Vtu0rY0v6G4cajtN2fm0hqA229q6elIuG6WLvvzq8-qJUWOEF3frSfX944dv55-bi8tPy_Ozi0azdpGaDlpsCNGGC6SI1pgzhJFaUNKuhBAKVspQho3pzIpghbkRutULxQjrQHSEnlTL2bf36kpugp1U2EqvrNwPfBikCiWBESQ2wDrVL5jguu2REaLTdMWoYVQbJHDxej97bfJqgl6DS0GNB6aHO86u5eBvJEYUl4vjxeHNnUPwPzLEJCcbd9EqB-VCJBGUMF5Ot0Nf_4Ne-RxcyWpHCd61AqG_1KDKCawzvnxY70zlGWeMYsE6UajT_1Dl6WGy2jswtswPBG8PBIVJcJsGlWOUy69fDlkyszr4GAOY-0AwkruWy7nlsrRc7lsuWRG9ehjlveRPrelvpbD8Jg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2838764800</pqid></control><display><type>article</type><title>Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Lee, Yi-Yen ; Luo, Shao-Ciao ; Lee, Chung-Hsin ; Tang, Chien-Lun ; Shen, Chiung-Chyi ; Cheng, Wen-Yu ; Yang, Yi-Chin ; Yang, Meng-Yin ; Yen, Chun-Ming</creator><creatorcontrib>Lee, Yi-Yen ; Luo, Shao-Ciao ; Lee, Chung-Hsin ; Tang, Chien-Lun ; Shen, Chiung-Chyi ; Cheng, Wen-Yu ; Yang, Yi-Chin ; Yang, Meng-Yin ; Yen, Chun-Ming</creatorcontrib><description>Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing processes and treatment strategies are major limitations. Our study used tumor lysate as a tumor-associated antigen source and DCs and CIK cells in coculture. We developed an efficient method to obtain autologous DCs- and CIK cells from peripheral blood. We used flow cytometry to assess DC activation and the cytometric bead array assay to quantify cytokines secreted by CIK cells.
We evaluated the antitumor activity of DC- CIK coculture in vitro with the K562 cell line. We demonstrated that a manufacturing process employing frozen immature DCs can yield the lowest loss with the highest economic benefits. DC-CIK coculture can effectively upgrade CIK cells' immunological specificity to tumors in the presence of tumor-associated antigens.
In vitro experiments revealed that when the DC- CIK cell ratio was 1: 20 in the coculture, CIK cells secreted the highest number of cytokines on the 14th day and the antitumor immune effect showed the highest potency. CIK cells' cytotoxicity to K562 cells was highest when the CIK: K562 cell ratio was 25: 1. We developed an efficient manufacturing process for DC- CIK coculture, while also establishing the optimal DC- CIK cell ratio for immunological activity and the best cytotoxic CIK: K562 cell ratio.</description><identifier>ISSN: 1471-2172</identifier><identifier>EISSN: 1471-2172</identifier><identifier>DOI: 10.1186/s12865-023-00552-5</identifier><identifier>PMID: 37386444</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antibodies ; Antigen (tumor-associated) ; Antigens ; Antitumor activity ; Cancer immunotherapy ; Cancer therapies ; Cancer vaccines ; Cell activation ; Cell culture ; Cell-mediated cytotoxicity ; Cloning ; Coculture Techniques ; Cytokine-Induced Killer Cells ; Cytokines ; Cytotoxic cell ; Cytotoxicity ; Dendritic Cells ; Dosage and administration ; Flow cytometry ; Humans ; Immunotherapy ; Lymphocytes ; Manufacturing ; Neoplasms ; Patient outcomes ; Patients ; Peripheral blood ; Peripheral blood monocyte ; Tumor-associated antigen</subject><ispartof>BMC immunology, 2023-06, Vol.24 (1), p.14-14, Article 14</ispartof><rights>2023. The Author(s).</rights><rights>COPYRIGHT 2023 BioMed Central Ltd.</rights><rights>2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c549t-6e41f22cf780a2cc175010a9324b888aebaf351ff6fb21a17f8c4c9a5256e8623</cites><orcidid>0000-0002-2544-8181</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311787/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2838764800?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37386444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Yi-Yen</creatorcontrib><creatorcontrib>Luo, Shao-Ciao</creatorcontrib><creatorcontrib>Lee, Chung-Hsin</creatorcontrib><creatorcontrib>Tang, Chien-Lun</creatorcontrib><creatorcontrib>Shen, Chiung-Chyi</creatorcontrib><creatorcontrib>Cheng, Wen-Yu</creatorcontrib><creatorcontrib>Yang, Yi-Chin</creatorcontrib><creatorcontrib>Yang, Meng-Yin</creatorcontrib><creatorcontrib>Yen, Chun-Ming</creatorcontrib><title>Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing</title><title>BMC immunology</title><addtitle>BMC Immunol</addtitle><description>Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing processes and treatment strategies are major limitations. Our study used tumor lysate as a tumor-associated antigen source and DCs and CIK cells in coculture. We developed an efficient method to obtain autologous DCs- and CIK cells from peripheral blood. We used flow cytometry to assess DC activation and the cytometric bead array assay to quantify cytokines secreted by CIK cells.
We evaluated the antitumor activity of DC- CIK coculture in vitro with the K562 cell line. We demonstrated that a manufacturing process employing frozen immature DCs can yield the lowest loss with the highest economic benefits. DC-CIK coculture can effectively upgrade CIK cells' immunological specificity to tumors in the presence of tumor-associated antigens.
In vitro experiments revealed that when the DC- CIK cell ratio was 1: 20 in the coculture, CIK cells secreted the highest number of cytokines on the 14th day and the antitumor immune effect showed the highest potency. CIK cells' cytotoxicity to K562 cells was highest when the CIK: K562 cell ratio was 25: 1. We developed an efficient manufacturing process for DC- CIK coculture, while also establishing the optimal DC- CIK cell ratio for immunological activity and the best cytotoxic CIK: K562 cell ratio.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Antigen (tumor-associated)</subject><subject>Antigens</subject><subject>Antitumor activity</subject><subject>Cancer immunotherapy</subject><subject>Cancer therapies</subject><subject>Cancer vaccines</subject><subject>Cell activation</subject><subject>Cell culture</subject><subject>Cell-mediated cytotoxicity</subject><subject>Cloning</subject><subject>Coculture Techniques</subject><subject>Cytokine-Induced Killer Cells</subject><subject>Cytokines</subject><subject>Cytotoxic cell</subject><subject>Cytotoxicity</subject><subject>Dendritic Cells</subject><subject>Dosage and administration</subject><subject>Flow cytometry</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Manufacturing</subject><subject>Neoplasms</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Peripheral blood monocyte</subject><subject>Tumor-associated antigen</subject><issn>1471-2172</issn><issn>1471-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkstu1DAYhSMEoqXwAixQJDawSPEljj0rVFVcRqpUicva8ji_M24Te_Cl6vBevB-eSSkdhLJw9Ps7J_HxqaqXGJ1iLLp3ERPRsQYR2iDEGGnYo-oYtxw3BHPy-MH7UfUsxiuEMBdEPK2OKKeia9v2uPp1uUl2sj-tG-qUJx8aFaPXViXoa-WSHcA1sSB5nEc5-dEPPse6B9cHm6yuNYxjgftab5O_tg4a6_qsC35txxHCDGiv85hygDr5GtxaOQ17RfK3Vtu0rY0v6G4cajtN2fm0hqA229q6elIuG6WLvvzq8-qJUWOEF3frSfX944dv55-bi8tPy_Ozi0azdpGaDlpsCNGGC6SI1pgzhJFaUNKuhBAKVspQho3pzIpghbkRutULxQjrQHSEnlTL2bf36kpugp1U2EqvrNwPfBikCiWBESQ2wDrVL5jguu2REaLTdMWoYVQbJHDxej97bfJqgl6DS0GNB6aHO86u5eBvJEYUl4vjxeHNnUPwPzLEJCcbd9EqB-VCJBGUMF5Ot0Nf_4Ne-RxcyWpHCd61AqG_1KDKCawzvnxY70zlGWeMYsE6UajT_1Dl6WGy2jswtswPBG8PBIVJcJsGlWOUy69fDlkyszr4GAOY-0AwkruWy7nlsrRc7lsuWRG9ehjlveRPrelvpbD8Jg</recordid><startdate>20230629</startdate><enddate>20230629</enddate><creator>Lee, Yi-Yen</creator><creator>Luo, Shao-Ciao</creator><creator>Lee, Chung-Hsin</creator><creator>Tang, Chien-Lun</creator><creator>Shen, Chiung-Chyi</creator><creator>Cheng, Wen-Yu</creator><creator>Yang, Yi-Chin</creator><creator>Yang, Meng-Yin</creator><creator>Yen, Chun-Ming</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2544-8181</orcidid></search><sort><creationdate>20230629</creationdate><title>Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing</title><author>Lee, Yi-Yen ; Luo, Shao-Ciao ; Lee, Chung-Hsin ; Tang, Chien-Lun ; Shen, Chiung-Chyi ; Cheng, Wen-Yu ; Yang, Yi-Chin ; Yang, Meng-Yin ; Yen, Chun-Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-6e41f22cf780a2cc175010a9324b888aebaf351ff6fb21a17f8c4c9a5256e8623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Antigen (tumor-associated)</topic><topic>Antigens</topic><topic>Antitumor activity</topic><topic>Cancer immunotherapy</topic><topic>Cancer therapies</topic><topic>Cancer vaccines</topic><topic>Cell activation</topic><topic>Cell culture</topic><topic>Cell-mediated cytotoxicity</topic><topic>Cloning</topic><topic>Coculture Techniques</topic><topic>Cytokine-Induced Killer Cells</topic><topic>Cytokines</topic><topic>Cytotoxic cell</topic><topic>Cytotoxicity</topic><topic>Dendritic Cells</topic><topic>Dosage and administration</topic><topic>Flow cytometry</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Manufacturing</topic><topic>Neoplasms</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Peripheral blood monocyte</topic><topic>Tumor-associated antigen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Yi-Yen</creatorcontrib><creatorcontrib>Luo, Shao-Ciao</creatorcontrib><creatorcontrib>Lee, Chung-Hsin</creatorcontrib><creatorcontrib>Tang, Chien-Lun</creatorcontrib><creatorcontrib>Shen, Chiung-Chyi</creatorcontrib><creatorcontrib>Cheng, Wen-Yu</creatorcontrib><creatorcontrib>Yang, Yi-Chin</creatorcontrib><creatorcontrib>Yang, Meng-Yin</creatorcontrib><creatorcontrib>Yen, Chun-Ming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Science (Gale in Context)</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Yi-Yen</au><au>Luo, Shao-Ciao</au><au>Lee, Chung-Hsin</au><au>Tang, Chien-Lun</au><au>Shen, Chiung-Chyi</au><au>Cheng, Wen-Yu</au><au>Yang, Yi-Chin</au><au>Yang, Meng-Yin</au><au>Yen, Chun-Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing</atitle><jtitle>BMC immunology</jtitle><addtitle>BMC Immunol</addtitle><date>2023-06-29</date><risdate>2023</risdate><volume>24</volume><issue>1</issue><spage>14</spage><epage>14</epage><pages>14-14</pages><artnum>14</artnum><issn>1471-2172</issn><eissn>1471-2172</eissn><abstract>Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing processes and treatment strategies are major limitations. Our study used tumor lysate as a tumor-associated antigen source and DCs and CIK cells in coculture. We developed an efficient method to obtain autologous DCs- and CIK cells from peripheral blood. We used flow cytometry to assess DC activation and the cytometric bead array assay to quantify cytokines secreted by CIK cells.
We evaluated the antitumor activity of DC- CIK coculture in vitro with the K562 cell line. We demonstrated that a manufacturing process employing frozen immature DCs can yield the lowest loss with the highest economic benefits. DC-CIK coculture can effectively upgrade CIK cells' immunological specificity to tumors in the presence of tumor-associated antigens.
In vitro experiments revealed that when the DC- CIK cell ratio was 1: 20 in the coculture, CIK cells secreted the highest number of cytokines on the 14th day and the antitumor immune effect showed the highest potency. CIK cells' cytotoxicity to K562 cells was highest when the CIK: K562 cell ratio was 25: 1. We developed an efficient manufacturing process for DC- CIK coculture, while also establishing the optimal DC- CIK cell ratio for immunological activity and the best cytotoxic CIK: K562 cell ratio.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>37386444</pmid><doi>10.1186/s12865-023-00552-5</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-2544-8181</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2172 |
ispartof | BMC immunology, 2023-06, Vol.24 (1), p.14-14, Article 14 |
issn | 1471-2172 1471-2172 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_1fe56ad9587c4d0f886c3b53f53cf081 |
source | PubMed (Medline); Publicly Available Content Database |
subjects | Analysis Antibodies Antigen (tumor-associated) Antigens Antitumor activity Cancer immunotherapy Cancer therapies Cancer vaccines Cell activation Cell culture Cell-mediated cytotoxicity Cloning Coculture Techniques Cytokine-Induced Killer Cells Cytokines Cytotoxic cell Cytotoxicity Dendritic Cells Dosage and administration Flow cytometry Humans Immunotherapy Lymphocytes Manufacturing Neoplasms Patient outcomes Patients Peripheral blood Peripheral blood monocyte Tumor-associated antigen |
title | Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A36%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimizing%20tumor-associated%20antigen-stimulated%20autologous%20dendritic%20cell%20and%20cytokine-induced%20killer%20cell%20coculture%20to%20enhance%20cytotoxicity%20for%20cancer%20immunotherapy%20in%20manufacturing&rft.jtitle=BMC%20immunology&rft.au=Lee,%20Yi-Yen&rft.date=2023-06-29&rft.volume=24&rft.issue=1&rft.spage=14&rft.epage=14&rft.pages=14-14&rft.artnum=14&rft.issn=1471-2172&rft.eissn=1471-2172&rft_id=info:doi/10.1186/s12865-023-00552-5&rft_dat=%3Cgale_doaj_%3EA755318568%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c549t-6e41f22cf780a2cc175010a9324b888aebaf351ff6fb21a17f8c4c9a5256e8623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2838764800&rft_id=info:pmid/37386444&rft_galeid=A755318568&rfr_iscdi=true |